Stammdaten
Apogee Therapeutics, Inc. ist über ihre Tochtergesellschaft als Biotechnologieunternehmen tätig, das Biologika zur Behandlung von atopischer Dermatitis (AD), chronisch obstruktiver Lungenerkrankung (COPD) und damit verbundenen entzündlichen und Immunologie-Indikationen entwickelt. Das Unternehmen entwickelt in erster Linie APG777, einen subkutanen (SQ) monoklonalen Antikörper (mAb) mit verlängerter Halbwertszeit für AD; und APG808, einen SQ mAb mit verlängerter Halbwertszeit für COPD. Seine frühen Programme umfassen APG990, einen SQ monoklonalen Antikörper mit verlängerter Halbwertszeit zur Behandlung von AD; und APG222, SQ-Antikörper mit verlängerter Halbwertszeit für AD. Das Unternehmen wurde 2022 gegründet und hat seinen Sitz in Waltham, Massachusetts. KI
Unternehmen & Branche
| Name | Apogee Therapeutics, Inc. |
|---|---|
| Ticker | APGE |
| CIK | 0001974640 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Biotechnologie (Forschung) |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 03770N101 |
|---|---|
| ISIN | US03770N1019 |
| Typ | Common Stock |
| Marktkapitalisierung | 9,18 Mrd. USD |
| Beta | 0,24 |
Sitz & Kontakt
| Geschäftsadresse | 1 LETTERMAN DRIVE BUILDING B, SAN FRANCISCO, CA |
|---|---|
| Telefon | 650-394-5230 |
| EIN (IRS) | 93-4958665 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
| Frühere Namen | Apogee Therapeutics, LLC (bis 2023) |
Bewertung
| FCF-Rendite | -2,5 % vs. -5,5 % (2023) ▲ |
|---|
Qualität & Bilanz
| ROIC | -2.891,2 % vs. -4.129,1 % (2023) ▲ |
|---|
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2023. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|
| Bewertung | |||||
| FCF-Rendite | -5,5 % | -6,6 % | -4,5 % | -2,6 % | |
| Qualität & Bilanz | |||||
| ROIC | -4.129,1 % | -1.539,6 % | -2.891,2 % | -3.412,6 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
APGE
Apogee Therapeutics, Inc.
Effektiv
Schwach
Handelsvolumen
Hoch
Insider
0,0
Keine Insider-Käufe
Institutionell
32,7
45 neu, 111 erhöht, 683,8M $ netto
Aktivist
59,2
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 108.47 | +23.8 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 81.28 | +65.2 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 129.90 | EMA50: 115.10 | |
| MACD-Histogramm | Bärisch | 10 % | -1.742 | Bearisch | |
| RSI(14) | Bärisch | 10 % | 80.5 | Überkauft | |
| Stoch %K(14) | Bärisch | 5 % | 85.9 | Überkauft | |
| ADX(14)+DI | Bullisch | 10 % | 61.1 | +DI: 50.2 / −DI: 9.0 | |
| Z-Score(60) | Neutral | 5 % | 1.21 | In Range | |
| 52W-Position | Bullisch | 5 % | 100.0 % | Hoch 134.29 / Tief 34.65 | |
| Bollinger(20,2σ) | Neutral | 5 % | 76.3 % | Upper 134.81 / Mid 133.70 / Lower 132.59 | |
| LinReg-Slope(60) | Bullisch | 10 % | +1.2551 | R²=0.76 / annualisiert +303.4 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-08 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -20.000 | 133,63 | -2.672.600,00 | -130,8% | |
| 2026-07-01 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -5.500 | 132,74 | -730.070,00 | -35,7% | |
| 2026-06-22 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -80.000 | 132,54 | -10.603.200,00 | -519,1% | |
| 2026-06-22 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -26.400 | 132,60 | -3.500.640,00 | -171,4% | |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -1.577 | 85,19 | -134.344,63 | -6,6% | |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -1.080 | 84,18 | -90.914,40 | -4,5% | |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -614 | 86,89 | -53.350,46 | -2,6% | |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -7.654 | 82,78 | -633.598,12 | -31,0% | |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -6.770 | 82,21 | -556.561,70 | -27,2% | |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -2.305 | 86,27 | -198.852,35 | -9,7% | |
| 2026-06-03 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -5.500 | 78,71 | -432.905,00 | -21,2% | |
| 2026-05-13 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -18.659 | 82,05 | -1.530.970,95 | -74,9% | |
| 2026-05-13 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -1.341 | 82,58 | -110.739,78 | -5,4% | |
| 2026-05-06 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -3.700 | 83,92 | -310.504,00 | -15,2% | |
| 2026-05-06 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -1.800 | 84,60 | -152.280,00 | -7,5% | |
| 2026-05-01 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -289 | 83,16 | -24.033,24 | -1,2% | |
| 2026-05-01 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -900 | 82,60 | -74.340,00 | -3,6% | |
| 2026-05-01 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -811 | 81,02 | -65.707,22 | -3,2% | |
| 2026-04-16 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -2.000 | 90,00 | -180.000,00 | -8,8% | |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -17.800 | 82,48 | -1.468.144,00 | -71,9% | |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -2.000 | 83,26 | -166.520,00 | -8,2% | |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -200 | 85,00 | -17.000,00 | -0,8% | |
| 2026-04-01 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -2.702 | 85,33 | -230.561,66 | -11,3% | |
| 2026-04-01 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -2.698 | 84,31 | -227.468,38 | -11,1% | |
| 2026-04-01 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -100 | 85,89 | -8.589,00 | -0,4% | |
| 2026-04-01 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -1.100 | 85,46 | -94.006,00 | -4,6% | |
| 2026-04-01 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -900 | 84,46 | -76.014,00 | -3,7% | |
| 2026-03-25 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -2.000 | 85,00 | -170.000,00 | -8,3% | |
| 2026-03-11 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -8.219 | 74,83 | -615.027,77 | -30,1% | |
| 2026-03-11 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -8.363 | 74,29 | -621.287,27 | -30,4% | |
| 2026-03-11 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -3.418 | 75,86 | -259.289,48 | -12,7% | |
| 2026-03-04 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -2.075 | 71,98 | -149.358,50 | -7,3% | |
| 2026-03-04 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -3.225 | 70,33 | -226.814,25 | -11,1% | |
| 2026-03-04 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -200 | 73,26 | -14.652,00 | -0,7% | |
| 2026-03-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -300 | 69,43 | -20.829,00 | -1,0% | |
| 2026-03-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -994 | 70,45 | -70.027,30 | -3,4% | |
| 2026-03-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -406 | 71,66 | -29.093,96 | -1,4% | |
| 2026-03-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -300 | 68,27 | -20.481,00 | -1,0% | |
| 2026-02-11 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -955 | 64,99 | -62.065,45 | -3,0% | |
| 2026-02-11 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -7.551 | 63,73 | -481.225,23 | -23,6% | |
| 2026-02-11 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -11.494 | 62,96 | -723.662,24 | -35,4% | |
| 2026-02-04 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -1.420 | 65,83 | -93.478,60 | -4,6% | |
| 2026-02-04 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -100 | 67,88 | -6.788,00 | -0,3% | |
| 2026-02-04 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -200 | 68,94 | -13.788,00 | -0,7% | |
| 2026-02-04 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -1.299 | 66,85 | -86.838,15 | -4,3% | |
| 2026-02-04 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -2.481 | 64,88 | -160.967,28 | -7,9% | |
| 2026-02-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -792 | 65,21 | -51.646,32 | -2,5% | |
| 2026-02-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -100 | 66,89 | -6.689,00 | -0,3% | |
| 2026-02-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -1.108 | 66,15 | -73.294,20 | -3,6% | |
| 2026-01-22 | Fairmount Funds Management LLC | Director | Open Market Sale | -1.750.000 | 76,30 | -133.525.000,00 | -6536,7% | |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -1.854 | 82,41 | -152.788,14 | -7,5% | |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -470 | 83,79 | -39.381,30 | -1,9% | |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -1.440 | 78,64 | -113.241,60 | -5,5% | |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -8.476 | 79,82 | -676.554,32 | -33,1% | |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -5.386 | 83,16 | -447.899,76 | -21,9% | |
| 2026-01-14 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -2.374 | 81,00 | -192.294,00 | -9,4% | |
| 2026-01-07 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -100 | 80,06 | -8.006,00 | -0,4% | |
| 2026-01-07 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -14.820 | 77,90 | -1.154.478,00 | -56,5% | |
| 2026-01-07 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -2.954 | 77,13 | -227.842,02 | -11,2% | |
| 2026-01-07 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -826 | 79,04 | -65.287,04 | -3,2% | |
| 2026-01-06 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -2.000 | 80,00 | -160.000,00 | -7,8% | |
| 2026-01-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -1.920 | 74,13 | -142.329,60 | -7,0% | |
| 2026-01-02 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -4.080 | 75,20 | -306.816,00 | -15,0% | |
| 2025-12-19 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -1.500 | 80,00 | -120.000,00 | -5,9% | |
| 2025-12-10 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -9.435 | 74,88 | -706.492,80 | -34,6% | |
| 2025-12-10 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -10.005 | 75,79 | -758.278,95 | -37,1% | |
| 2025-12-10 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -560 | 76,58 | -42.884,80 | -2,1% | |
| 2025-12-04 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -1.500 | 75,00 | -112.500,00 | -5,5% | |
| 2025-12-04 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -10.900 | 75,00 | -817.500,00 | -40,0% | |
| 2025-12-04 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -40.000 | 75,01 | -3.000.400,00 | -146,9% | |
| 2025-11-25 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -1.500 | 70,00 | -105.000,00 | -5,1% | |
| 2025-11-14 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -2.000 | 65,00 | -130.000,00 | -6,4% | |
| 2025-11-13 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -1.786 | 63,89 | -114.107,54 | -5,6% | |
| 2025-11-13 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -100 | 64,52 | -6.452,00 | -0,3% | |
| 2025-11-13 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -14.774 | 63,14 | -932.830,36 | -45,7% | |
| 2025-11-13 | HENDERSON MICHAEL THOMAS | Director, Officer, Chief Executive Officer | Open Market Sale | -3.340 | 61,93 | -206.846,20 | -10,1% | |
| 2025-11-11 | Henderson Jane | Officer, Chief Financial Officer | Open Market Sale | -1.000 | 60,00 | -60.000,00 | -2,9% | |
| 2025-11-05 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -678 | 56,51 | -38.313,78 | -1,9% | |
| 2025-11-05 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -5.607 | 55,58 | -311.637,06 | -15,3% | |
| 2025-11-05 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -2.300 | 53,62 | -123.326,00 | -6,0% | |
| 2025-11-05 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -2.200 | 54,83 | -120.626,00 | -5,9% | |
| 2025-10-01 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -5.110 | 39,80 | -203.378,00 | -10,0% | |
| 2025-09-03 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -190 | 38,55 | -7.324,50 | -0,4% | |
| 2025-09-03 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -2.535 | 37,82 | -95.873,70 | -4,7% | |
| 2025-08-06 | Dambkowski Carl | Officer, Chief Medical Officer | Open Market Sale | -2.725 | 37,78 | -102.950,50 | -5,0% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| FMR LLC | 9.262.291 | 0 | 9.262.291 | 779.606.994 | Neu | +100,0% | |
| Venrock Adviser, LLC | 8.493.321 | 0 | 8.493.321 | 714.882.829 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 4.375.703 | 0 | 4.375.703 | 368.302.921 | Neu | +100,0% | |
| BlackRock, Inc. | 4.085.651 | 0 | 4.085.651 | 343.889.202 | Neu | +100,0% | |
| RTW INVESTMENTS, LP | 2.782.097 | 0 | 2.782.097 | 234.169.104 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.502.095 | 0 | 2.502.095 | 210.601.336 | Neu | +100,0% | |
| Janus Henderson Group Ltd. | 2.360.596 | 0 | 2.360.596 | 198.808.884 | Neu | +100,0% | |
| STATE STREET CORP | 2.162.964 | 0 | 2.162.964 | 182.056.680 | Neu | +100,0% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1.920.800 | 0 | 1.920.800 | 161.673.736 | Neu | +100,0% | |
| PERCEPTIVE ADVISORS LLC | 1.540.384 | 0 | 1.540.384 | 129.654.121 | Neu | +100,0% | |
| Paradigm Biocapital Advisors LP | 1.348.243 | 0 | 1.348.243 | 113.481.613 | Neu | +100,0% | |
| Affinity Asset Advisors, LLC | 1.284.926 | 0 | 1.284.926 | 108.152.221 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.217.289 | 0 | 1.217.289 | 102.483.956 | Neu | +100,0% | |
| UBS Group AG | 1.144.328 | 0 | 1.144.328 | 96.318.088 | Neu | +100,0% | |
| Vestal Point Capital, LP | 1.100.000 | 0 | 1.100.000 | 92.587.000 | Neu | +100,0% | |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 1.064.483 | 0 | 1.064.483 | 89.597.516 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 900.871 | 0 | 900.871 | 75.826.311 | Neu | +100,0% | |
| ALLIANCEBERNSTEIN L.P. | 990.297 | 0 | 990.297 | 74.747.618 | Neu | +100,0% | |
| MERCER GLOBAL ADVISORS INC /ADV | 831.428 | 0 | 831.428 | 69.981.295 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 652.602 | 0 | 652.602 | 54.929.510 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 652.590 | 0 | 652.590 | 54.928.500 | Neu | +100,0% | |
| MORGAN STANLEY | 595.032 | 0 | 595.032 | 50.083.937 | Neu | +100,0% | |
| JENNISON ASSOCIATES LLC | 585.016 | 0 | 585.016 | 49.240.797 | Neu | +100,0% | |
| Remedium Capital Partners, LLC | 583.591 | 0 | 583.591 | 49.120.854 | Neu | +100,0% | |
| First Light Asset Management, LLC | 576.684 | 0 | 576.684 | 48.539.492 | Neu | +100,0% | |
| EVENTIDE ASSET MANAGEMENT, LLC | 557.423 | 0 | 557.423 | 46.918.294 | Neu | +100,0% | |
| Polar Capital Holdings Plc | 539.177 | 0 | 539.177 | 45.382.528 | Neu | +100,0% | |
| First Turn Management, LLC | 513.770 | 0 | 513.770 | 43.244.021 | Neu | +100,0% | |
| BRAIDWELL LP | 478.667 | 0 | 478.667 | 40.289.401 | Neu | +100,0% | |
| Novo Holdings A/S | 450.000 | 0 | 450.000 | 37.876.500 | Neu | +100,0% | |
| FEDERATED HERMES, INC. | 442.738 | 0 | 442.738 | 37.265.257 | Neu | +100,0% | |
| BALYASNY ASSET MANAGEMENT L.P. | 438.654 | 0 | 438.654 | 36.921.507 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 420.684 | 0 | 420.684 | 35.408.972 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 405.538 | 0 | 405.538 | 34.134.157 | Neu | +100,0% | |
| Caption Management, LLC | 395.400 | 0 | 395.400 | 33.280.818 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 390.879 | 0 | 390.879 | 32.900.285 | Neu | +100,0% | |
| Opaleye Management Inc. | 390.000 | 0 | 390.000 | 32.826.300 | Neu | +100,0% | |
| GREAT POINT PARTNERS LLC | 374.000 | 0 | 374.000 | 31.479.580 | Neu | +100,0% | |
| LOOMIS SAYLES & CO L P | 362.781 | 0 | 362.781 | 30.535.277 | Neu | +100,0% | |
| Capital World Investors | 348.674 | 0 | 348.674 | 29.347.891 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 318.399 | 0 | 318.399 | 26.799.644 | Neu | +100,0% | |
| Fairmount Funds Management LLC | 298.647 | 0 | 298.647 | 25.137.118 | Neu | +100,0% | |
| Deep Track Capital, LP | 285.000 | 0 | 285.000 | 23.988.450 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 281.386 | 0 | 281.386 | 23.684.260 | Neu | +100,0% | |
| Woodline Partners LP | 261.120 | 0 | 261.120 | 21.978.470 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 261.050 | 0 | 261.050 | 21.972.579 | Neu | +100,0% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 250.000 | 0 | 250.000 | 21.042.500 | Neu | +100,0% | |
| Candriam S.C.A. | 223.541 | 0 | 223.541 | 18.815.446 | Neu | +100,0% | |
| DIADEMA PARTNERS LP | 222.500 | 0 | 222.500 | 18.727.825 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 220.099 | 0 | 220.099 | 18.525.733 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Chicago Capital Management, LLC | 97.100 | 0 | +100,0% | 9.807.420 | 23,50 | 76 % | 1 Q |
| CREDIT INDUSTRIEL ET COMMERCIAL | 63.424 | 0 | +100,0% | 8.418.268 | 20,17 | 100 % | 1 Q |
| ABC ARBITRAGE SA | 52.918 | 0 | +100,0% | 7.023.806 | 16,83 | 0 % | 1 Q |
| Transmarket Holdings LP | 34.493 | 0 | +100,0% | 4.578.256 | 10,97 | 100 % | 1 Q |
| Erste Asset Management GmbH | 24.000 | 24.000 | 0,0% | 3.182.640 | 7,62 | 100 % | 7 Q |
| Police & Firemen's Retirement System of New Jersey | 13.302 | 11.138 | +19,4% | 1.765.574 | 4,23 | 100 % | 7 Q |
| AlphaCentric Advisors LLC | 11.533 | 11.369 | +1,4% | 1.530.775 | 3,67 | 0 % | 5 Q |
| China Universal Asset Management Co., Ltd. | 9.852 | 9.731 | +1,2% | 1.307.656 | 3,13 | 100 % | 11 Q |
| Marks Group Wealth Management, Inc | 9.088 | 8.243 | +10,3% | 1.206.250 | 2,89 | 0 % | 2 Q |
| SBI Okasan Asset Management Co.Ltd. | 7.100 | 7.100 | 0,0% | 941.531 | 2,26 | 100 % | 2 Q |
| COMMONWEALTH EQUITY SERVICES, LLC | 5.683 | 5.915 | -3,9% | 754.300 | 1,81 | – | 7 Q |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | 3.000 | 0 | +100,0% | 398.190 | 0,95 | 100 % | 1 Q |
| Mirae Asset Global Investments Co., Ltd. | 2.769 | 2.860 | -3,2% | 367.529 | 0,88 | 100 % | 9 Q |
| Swiss Life Asset Management Ltd | 2.183 | 0 | +100,0% | 289.750 | 0,69 | 100 % | 1 Q |
| GAMMA Investing LLC | 309 | 220 | +40,5% | 41.014 | 0,10 | 100 % | 10 Q |
| Versant Capital Management, Inc | 240 | 229 | +4,8% | 31.855 | 0,08 | 100 % | 6 Q |
| EverSource Wealth Advisors, LLC | 203 | 645 | -68,5% | 26.945 | 0,06 | 100 % | 7 Q |
| Sterling Capital Management LLC | 158 | 289 | -45,3% | 20.971 | 0,05 | 0 % | 8 Q |
| Handelsbanken Fonder AB | 86.300 | 21.100 | +309,0% | 11.455 | 0,03 | 0 % | 9 Q |
| IFP Advisors, Inc | 72 | 27 | +166,7% | 9.557 | 0,02 | 100 % | 7 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 31 | 0,4 | 42 |
| 31.03.2026 | ✓ | 222 | 86,3 | 6.276 |
| 31.12.2025 | ✓ | 205 | 73,4 | 8.974 |
| 30.09.2025 | ✓ | 171 | 62,2 | 9.996 |
| 30.06.2025 | ✓ | 181 | 58,9 | 10.215 |
| 31.03.2025 | ✓ | 166 | 75,6 | 9.249 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| BALYASNY ASSET MANAGEMENT L.P. | 438.654 | 36.921.507 |
| Deep Track Capital, LP | 285.000 | 23.988.450 |
| Alyeska Investment Group, L.P. | 75.000 | 6.312.750 |
| Rhenman & Partners Asset Management AB | 75.000 | 6.312.750 |
| WCM INVESTMENT MANAGEMENT, LLC | 76.030 | 5.985.082 |
| FIFTH THIRD BANCORP | 63.800 | 5.370.012 |
| Holocene Advisors, LP | 57.473 | 4.837.502 |
| Lisanti Capital Growth, LLC | 52.260 | 4.398.724 |
| Squarepoint Ops LLC | 38.348 | 3.227.751 |
| Burkehill Global Management, LP | 30.000 | 2.525.100 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 10.300.984 | 7.568.528 | +277.0 % | 867.034 |
| FMR LLC | 9.262.291 | 1.037.253 | +12.6 % | 779.606.994 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 1.064.483 | 584.030 | +121.6 % | 89.597.516 |
| Vestal Point Capital, LP | 1.100.000 | 550.000 | +100.0 % | 92.587.000 |
| STATE STREET CORP | 2.162.964 | 472.778 | +28.0 % | 182.056.680 |
| FEDERATED HERMES, INC. | 442.738 | 314.807 | +246.1 % | 37.265.257 |
| BlackRock, Inc. | 4.085.651 | 301.657 | +8.0 % | 343.889.202 |
| Janus Henderson Group Ltd. | 2.360.596 | 297.992 | +14.4 % | 198.808.884 |
| First Light Asset Management, LLC | 576.684 | 291.693 | +102.4 % | 48.539.492 |
| Paradigm Biocapital Advisors LP | 1.348.243 | 225.000 | +20.0 % | 113.481.613 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 298.647 | -1.750.000 | -85.4 % | 25.137.118 |
| PERCEPTIVE ADVISORS LLC | 1.540.384 | -790.267 | -33.9 % | 129.654.121 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.375.703 | -370.882 | -7.8 % | 368.302.921 |
| MORGAN STANLEY | 595.032 | -295.232 | -33.2 % | 50.083.937 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1.920.800 | -262.904 | -12.0 % | 161.673.736 |
| CITADEL ADVISORS LLC | 598.902 | -168.079 | -21.9 % | 50.409.581 |
| Novo Holdings A/S | 450.000 | -120.000 | -21.1 % | 37.876.500 |
| ALLIANCEBERNSTEIN L.P. | 990.297 | -103.360 | -9.5 % | 74.747.618 |
| BRAIDWELL LP | 478.667 | -96.400 | -16.8 % | 40.289.401 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.143.152 | -93.983 | -7.6 % | 96.221 |
Zusätzlich aktuell von 165 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck | Δ-Balken |
|---|---|---|---|---|---|---|---|
| 08.07.2026 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 1,30 % | 772.969 | -15,50 pp | – | |
| 08.07.2026 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 0,90 % | 564.326 | -7,80 pp | – | |
| 08.07.2026 | Abigail P. Johnson (+1) | Passiv (13G/A) | 4,00 % | 2.493.137 | -11,00 pp | – | |
| 23.06.2026 | Peter Evan Harwin (+1) | Aktivist (13D/A) | 9,99 % | 6.808.789 | 0,00 pp | Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following at… | |
| 23.06.2026 | Fairmount Healthcare Fund II L.P. (+1) | Aktivist (13D/A) | 9,84 % | 6.713.519 | 0,00 pp | Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following at… | |
| 08.04.2026 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 16,80 % | 10.291.220 | +5,50 pp | – | |
| 27.03.2026 | Fairmount Healthcare Fund II L.P. (+1) | Aktivist (13D/A) | 9,84 % | 6.666.332 | +0,02 pp | – | |
| 27.03.2026 | Peter Evan Harwin (+1) | Aktivist (13D/A) | 9,99 % | 6.764.974 | 0,00 pp | – | |
| 26.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -5,21 pp | – | |
| 06.03.2026 | T. Rowe Price Investment Management, Inc. | Passiv (13G) | 11,30 % | 6.213.827 | Neu | – | |
| 17.02.2026 | RTW Investments, LP (+1) | Passiv (13G/A) | 4,90 % | 2.712.097 | Neu | – | |
| 10.02.2026 | Wellington Management Company LLP | Passiv (13G/A) | 8,30 % | 4.746.585 | -2,00 pp | – | |
| 10.02.2026 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 8,70 % | 4.746.585 | -1,90 pp | – | |
| 30.01.2026 | The Vanguard Group | Passiv (13G) | 5,21 % | 2.857.824 | Neu | – | |
| 22.01.2026 | Peter Evan Harwin (+1) | Aktivist (13D/A) | 9,99 % | 6.047.027 | 0,00 pp | – | |
| 22.01.2026 | Fairmount Healthcare Fund II L.P. (+1) | Aktivist (13D/A) | 9,82 % | 5.948.385 | +0,01 pp | – | |
| 14.11.2025 | DRIEHAUS CAPITAL MANAGEMENT LLC | Passiv (13G/A) | 4,68 % | 2.158.502 | +4,68 pp | – | |
| 14.10.2025 | Fairmount Healthcare Fund II L.P. (+1) | Aktivist (13D/A) | 9,81 % | 5.678.239 | Neu | – | |
| 14.10.2025 | Peter Evan Harwin (+1) | Aktivist (13D/A) | 9,99 % | 5.776.881 | Neu | – | |
| 06.08.2025 | Abigail P. Johnson (+1) | Passiv (13G/A) | 15,00 % | 6.907.100 | Neu | – | |
| 05.08.2025 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 10,60 % | 4.885.146 | +2,30 pp | – | |
| 05.08.2025 | Wellington Management Company LLP | Passiv (13G/A) | 10,30 % | 4.885.146 | +2,30 pp | – | |
| 05.08.2025 | Wellington Management Company LLP | Passiv (13G/A) | 8,00 % | 3.805.710 | -3,60 pp | – | |
| 05.08.2025 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 8,30 % | 3.805.710 | -3,60 pp | – | |
| 16.07.2025 | BlackRock, Inc. | Passiv (13G/A) | 5,50 % | 2.518.725 | Neu | – | |
| 12.05.2025 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 11,90 % | 5.485.754 | +1,20 pp | – | |
| 12.05.2025 | Wellington Management Company LLP | Passiv (13G/A) | 11,60 % | 5.485.754 | +1,16 pp | – | |
| 14.02.2025 | Roderick Wong, M.D. (+1) | Passiv (13G) | 6,00 % | 2.712.097 | Neu | – | |
| 14.11.2024 | Deep Track Biotechnology Master Fund, Ltd. (+2) | Passiv (13G/A) | 2,22 % | 1.000.000 | -4,03 pp | – | |
| 14.11.2024 | RA Capital Management, L.P. (+2) | Passiv (13G/A) | 3,40 % | 1.961.863 | -1,90 pp | – | |
| 14.11.2024 | DRIEHAUS CAPITAL MANAGEMENT LLC | Passiv (13G) | 0,00 % | 2.533.607 | Neu | – | |
| 08.11.2024 | . BlackRock, Inc. | Passiv (13G) | 6,60 % | 2.975.917 | 0,00 pp | – | |
| 04.11.2024 | Access Industries Management, LLC (+3) | Passiv (13G/A) | 4,87 % | 2.190.364 | Neu | – | |
| 22.10.2024 | . BlackRock, Inc. | Passiv (13G) | 6,60 % | 2.975.917 | Neu | – | |
| 04.10.2024 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G) | 10,70 % | 4.814.400 | Neu | – | |
| 04.10.2024 | Wellington Management Company LLP | Passiv (13G) | 10,44 % | 4.699.376 | Neu | – | |
| 14.02.2024 | Deep Track Biotechnology Master Fund, Ltd. (+2) | Passiv (13G/A) | 6,25 % | 2.323.456 | -2,62 pp | – | |
| 14.02.2024 | RA Capital Management, L.P. (+2) | Passiv (13G) | 5,30 % | 1.977.901 | Neu | – | |
| 03.11.2023 | Access Industries Management, LLC (+3) | Passiv (13G) | 5,22 % | 1.940.364 | Neu | – | |
| 28.07.2023 | Venrock Healthcare Capital Partners III, L.P. (+6) | Aktivist (13D) | 9,99 % | 3.887.478 | Neu | – |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | -74.111.000 $ | -1,06 $ | 1.293.654.000 $ | – |
| 2025-12-31 | 10-K | – | -255.843.000 $ | -4,22 $ | 937.134.000 $ | – |
| 2025-09-30 | 10-Q | – | -65.021.000 $ | -1,11 $ | 626.159.000 $ | – |
| 2025-06-30 | 10-Q | – | -66.096.000 $ | -1,13 $ | 657.772.000 $ | – |
| 2025-03-31 | 10-Q | – | -55.339.000 $ | -0,95 $ | 714.162.000 $ | – |
| 2024-12-31 | 10-K | – | -182.146.000 $ | -3,30 $ | 753.951.000 $ | – |
| 2024-09-30 | 10-Q | – | -49.018.000 $ | -0,86 $ | 776.286.000 $ | – |
| 2024-06-30 | 10-Q | – | -33.816.000 $ | -0,60 $ | 800.657.000 $ | – |
| 2024-03-31 | 10-Q | – | -32.094.000 $ | -0,64 $ | 823.659.000 $ | – |
| 2023-12-31 | 10-K | – | -83.985.000 $ | -3,36 $ | 401.404.000 $ | – |
| 2023-09-30 | 10-Q | – | -20.840.000 $ | -0,51 $ | 426.421.000 $ | – |
| 2023-06-30 | 10-Q | – | -18.885.000 $ | -3,78 $ | 130.667.000 $ | – |
| 2023-03-31 | 10-Q | – | -12.525.000 $ | -2,51 $ | – | – |
| 2022-12-31 | 10-K | – | -39.785.000 $ | -16,16 $ | 152.055.000 $ | – |
| 2022-09-30 | 10-Q | – | -19.657.000 $ | -9,46 $ | – | – |
| 2022-06-30 | 10-Q | – | -1.816.000 $ | -1,45 $ | – | – |
| 2022-03-31 | 10-Q | – | -4.305.000 $ | – | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 11.05.2026 | – | -1,06 |
| Q3 2025 | 30.09.2025 | 10.11.2025 | – | -1,11 |
| Q2 2025 | 30.06.2025 | 11.08.2025 | – | -1,13 |
| Q1 2025 | 31.03.2025 | 12.05.2025 | – | -0,95 |
| Q3 2024 | 30.09.2024 | 12.11.2024 | – | -0,86 |
| Q2 2024 | 30.06.2024 | 12.08.2024 | – | -0,60 |
| Q1 2024 | 31.03.2024 | 13.05.2024 | – | -0,64 |
| Q3 2023 | 30.09.2023 | 13.11.2023 | – | -0,51 |
| Q2 2023 | 30.06.2023 | 28.08.2023 | – | -3,78 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 11.05.2026 | 10-Q | 31.03.2026 | 41 Tage | SEC » |
| 02.03.2026 | 10-K | 31.12.2025 | 61 Tage | SEC » |
| 10.11.2025 | 10-Q | 30.09.2025 | 41 Tage | SEC » |
| 11.08.2025 | 10-Q | 30.06.2025 | 42 Tage | SEC » |
| 12.05.2025 | 10-Q | 31.03.2025 | 42 Tage | SEC » |
| 03.03.2025 | 10-K | 31.12.2024 | 62 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 12.08.2024 | 10-Q | 30.06.2024 | 43 Tage | SEC » |
| 13.05.2024 | 10-Q | 31.03.2024 | 43 Tage | SEC » |
| 05.03.2024 | 10-K | 31.12.2023 | 65 Tage | SEC » |
| 13.11.2023 | 10-Q | 30.09.2023 | 44 Tage | SEC » |
| 28.08.2023 | 10-Q | 30.06.2023 | 59 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 25.03.2026 | Kapitalerhöhung | $350,0 Mio · $70,00/Aktie | SEC » |
| 23.03.2026 | Kapitalerhöhung | $300,0 Mio | SEC » |
| 10.10.2025 | Kapitalerhöhung | $300,0 Mio · $41,00/Aktie | SEC » |
| 08.10.2025 | Kapitalerhöhung | – | SEC » |
| 11.03.2024 | Börsengang | $420,0 Mio · $62,00/Aktie | SEC » |
| 17.07.2023 | Börsengang | $300,1 Mio · $17,00/Aktie | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 13.07.2026 | M&A-Abstimmung | 11.08.2026 a.o. HV | 10.07.2026 | DEFM14A | SEC » |
| 02.07.2026 | M&A-Abstimmung | — | — | PREM14A | SEC » |
| 26.06.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 22.06.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 22.06.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 24.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 24.04.2026 | HV-Einladung | 09.06.2026 Jahres-HV | 15.04.2026 | DEF 14A | SEC » |
| 29.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 29.04.2025 | HV-Einladung | 17.06.2025 Jahres-HV | 21.04.2025 | DEF 14A | SEC » |
| 28.05.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 24.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 24.04.2024 | HV-Einladung | 05.06.2024 Jahres-HV | 11.04.2024 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 24.04.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 28.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 21.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 22.06.2026 | M&A angekündigt | 0,70 | 90 | Apogee Therapeutics gibt Übernahmevereinbarung bekannt. Parent und Merger Sub haben Voting Agreement mit Aktionären zur Billigung der Fusion… 🔒 | SEC |
| 12.06.2026 | HV-Abstimmung | 0,10 | 25 | Apogee Therapeutics hielt am 9. Juni 2026 ihre Jahreshauptversammlung ab. Die Abstimmungsergebnisse sind im definitiven Proxy Statement doku… 🔒 | SEC |
| 27.05.2026 | Wesentliche Vereinbarung | 0,35 | 80 | Apogee Therapeutics sichert sich 100 Mio. USD Finanzierung durch Revenue Participation Right von Blackstone Life Sciences. Unternehmen entfe… 🔒 | SEC |
| 27.05.2026 | Guidance-Update | 0,75 | 80 | Apogee Therapeutics verkündet positive 16-Wochen-Ergebnisse aus Phase 2 APEX-Studie für zumilokibart (APG777) bei atopischer Dermatitis. Die… 🔒 | SEC |
| 11.05.2026 | Quartalszahlen | 0,00 | 50 | Apogee Therapeutics veröffentlichte einen Geschäftsbericht mit Finanzergebnissen für Q1 2026 (März 2026). Eine detaillierte Earnings-Mitteil… 🔒 | SEC |
| 24.04.2026 | Personalwechsel | -0,10 | 55 | Zwei Vorstandsmitglieder von Apogee Therapeutics, Andrew Gottesdiener und Peter Harwin, kündigen ihren Rücktritt zum 11. Mai 2026 an. | SEC |
| 25.03.2026 | Wesentliche Vereinbarung | 0,00 | 75 | Apogee Therapeutics kündigte ein öffentliches Angebot von 5 Millionen Stammaktien mit Jefferies, TD Securities und anderen Underwritern an. | SEC |
| 23.03.2026 | Sonstiges | 0,60 | 45 | Apogee Therapeutics kündigte positive Maintenancedaten aus Phase 2 Part A der APEX-Studie für zumilokibart (APG777) in moderater bis schwere… 🔒 | SEC |
| 02.03.2026 | Quartalszahlen | 0,00 | 55 | Apogee Therapeutics veröffentlichte am 2. März 2026 eine Pressemitteilung mit Geschäftsaktualisierung und Jahresergebnissen für das Jahr 202… 🔒 | SEC |
| 06.01.2026 | Sonstiges | 0,70 | 65 | Apogee Therapeutics gibt positive Interim-Daten aus Phase-1b-Studie des Anti-IL-13-Antikörpers zumilokibart bei leichtem bis mittlerem Asthm… 🔒 | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 1.496 | 132,61 | 198.385 |
| 2026-06-29 | 333.212 | 132,55 | 44.167.251 |
| 2026-06-24 | 32.232 | 132,88 | 4.282.988 |
| 2026-06-22 | 52.475 | 90,38 | 4.742.691 |
| 2026-06-18 | 49.990 | 88,43 | 4.420.616 |
| 2026-06-16 | 96 | 86,19 | 8.274 |
| 2026-06-08 | 26.344 | 86,92 | 2.289.820 |
| 2026-06-05 | 100 | 90,90 | 9.090 |
| 2026-06-03 | 375 | 78,71 | 29.516 |
| 2026-05-29 | 206 | 77,82 | 16.031 |
| 2026-05-28 | 660 | 77,75 | 51.315 |
| 2026-05-26 | 8 | 81,16 | 649 |
| 2026-05-22 | 45 | 82,43 | 3.709 |
| 2026-05-19 | 105 | 78,75 | 8.269 |
| 2026-05-14 | 1 | 83,94 | 84 |
| 2026-05-11 | 6 | 83,03 | 498 |
| 2026-05-06 | 1 | 83,29 | 83 |
| 2026-04-30 | 10.332 | 82,03 | 847.534 |
| 2026-04-21 | 2.373 | 90,92 | 215.753 |
| 2026-04-20 | 6.094 | 92,20 | 561.867 |
| 2026-04-17 | 59.996 | 90,55 | 5.432.638 |
| 2026-04-16 | 6 | 89,32 | 536 |
| 2026-04-15 | 251 | 88,47 | 22.206 |
| 2026-04-13 | 29.965 | 86,27 | 2.585.081 |
| 2026-04-07 | 75 | 84,01 | 6.301 |
| 2026-03-30 | 6 | 77,82 | 467 |
| 2026-03-27 | 1.757 | 78,42 | 137.784 |
| 2026-03-26 | 17.915 | 78,53 | 1.406.865 |
| 2026-03-25 | 11.244 | 73,00 | 820.812 |
| 2026-03-24 | 8.075 | 79,24 | 639.863 |
| 2026-03-23 | 27.054 | 66,04 | 1.786.646 |
| 2026-03-20 | 1.967 | 68,50 | 134.740 |
| 2026-03-19 | 14 | 66,77 | 935 |
| 2026-03-18 | 169 | 69,85 | 11.805 |
| 2026-03-16 | 7.246 | 71,90 | 520.987 |
| 2026-03-13 | 102 | 73,51 | 7.498 |
| 2026-03-10 | 7.536 | 74,94 | 564.748 |
| 2026-03-06 | 18.117 | 70,92 | 1.284.858 |
| 2026-03-04 | 21 | 68,50 | 1.439 |
| 2026-03-02 | 4.099 | 70,00 | 286.930 |
| 2026-02-25 | 184 | 71,27 | 13.114 |
| 2026-02-23 | 321 | 68,39 | 21.953 |
| 2026-02-19 | 124 | 70,27 | 8.713 |
| 2026-02-12 | 798 | 65,81 | 52.516 |
| 2026-02-04 | 2.014 | 68,89 | 138.744 |
| 2026-02-02 | 16.981 | 65,51 | 1.112.425 |
| 2026-01-30 | 10 | 69,98 | 700 |
| 2026-01-29 | 8.317 | 70,69 | 587.929 |